| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Molecular Medicine |
From the Johns Hopkins University School of Medicine (L.S., H. Kyo Lim, H. Kyoung Lim, V.M., T.B., M.P., S.B., S.R., M.A., D.N., R.R., A.S., D.E.B.), Baltimore Md; Department of Anesthesiology and Pain Medicine (H. Kyo Lim), Yonsei University, Wonju, Korea; University of Pittsburgh Medical Center (K.I., F.K.), Pa; University of Miami Miller School of Medicine (J.M.H.), Fla; and Department of Chemistry (L.D.C., D.W.C.), University of Pennsylvania, Philadelphia.
Correspondence to Dan E. Berkowitz, Johns Hopkins University School of Medicine, 720 Rutland Ave, Traylor 621, Baltimore MD 21209. E-mail dberkowi{at}jhmi.edu
Endothelial function is impaired in aging because of a decrease in NO bioavailability. This may be, in part, attributable to increased arginase activity, which reciprocally regulates NO synthase (NOS) by competing for the common substrate, L-arginine. However, the high Km of arginase (>1 mmol/L) compared with NOS (2 to 20 µmol/L) seemingly makes direct competition for substrate unlikely. One of the mechanisms by which NO exerts its effects is by posttranslational modification through S-nitrosylation of protein cysteines. We tested the hypothesis that arginase1 activity is modulated by this mechanism, which serves to alter its substrate affinity, allowing competition with NOS for L-arginine. We demonstrate that arginase1 activity is altered by S-nitrosylation, both in vitro and ex vivo. Furthermore, using site-directed mutagenesis we demonstrate that 2 cysteine residues (C168 and C303) are able to undergo nitrosylation. S-Nitrosylation of C303 stabilizes the arginase1 trimer and reduces its Km value 6-fold. Finally, arginase1 nitrosylation is increased (and thus its Km decreased) in blood vessels from aging rats, likely contributing to impaired NO bioavailability and endothelial dysfunction. This is mediated by inducible NOS, which is expressed in the aging endothelium. These findings suggest that S-nitrosylated arginase1 can compete with NOS for L-arginine and contribute to endothelial dysfunction in the aging cardiovascular system.
Key Words: arginase NO synthase S-nitrosylation aging
Related Article:
Circ. Res. 2007 101: 640-641.
This article has been cited by other articles:
![]() |
J. H. Kim, L. J. Bugaj, Y. J. Oh, T. J. Bivalacqua, S. Ryoo, K. G. Soucy, L. Santhanam, A. Webb, A. Camara, G. Sikka, et al. Arginase inhibition restores NOS coupling and reverses endothelial dysfunction and vascular stiffness in old rats J Appl Physiol, October 1, 2009; 107(4): 1249 - 1257. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Miki, A. Kumar, R. Yang, M. E. Killeen, and R. L. Delude Extracellular activation of arginase-1 decreases enterocyte inducible nitric oxide synthase activity during systemic inflammation Am J Physiol Gastrointest Liver Physiol, October 1, 2009; 297(4): G840 - G848. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. N. Huynh, K. L. Andrews, G. A. Head, S. M.L. Khong, D. N. Mayorov, A. J. Murphy, G. Lambert, H. Kiriazis, Q. Xu, X.-J. Du, et al. Arginase II Knockout Mouse Displays a Hypertensive Phenotype Despite a Decreased Vasoconstrictory Profile Hypertension, August 1, 2009; 54(2): 294 - 301. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. K. Mustafa, M. M. Gadalla, and S. H. Snyder Signaling by Gasotransmitters Sci. Signal., April 28, 2009; 2(68): re2 - re2. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-L. Balligand, O. Feron, and C. Dessy eNOS Activation by Physical Forces: From Short-Term Regulation of Contraction to Chronic Remodeling of Cardiovascular Tissues Physiol Rev, April 1, 2009; 89(2): 481 - 534. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Hughes, O. Wirth, K. Krajnak, R. Miller, S. Flavahan, D. E. Berkowitz, D. Welcome, and N. A. Flavahan Increased Oxidant Activity Mediates Vascular Dysfunction in Vibration Injury J. Pharmacol. Exp. Ther., January 1, 2009; 328(1): 223 - 230. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Santhanam, D. W. Christianson, D. Nyhan, and D. E. Berkowitz Arginase and vascular aging J Appl Physiol, November 1, 2008; 105(5): 1632 - 1642. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. L. Pierce and T. J. LaRocca Reduced vascular tetrahydrobiopterin (BH4) and endothelial function with ageing: is it time for a chronic BH4 supplementation trial in middle-aged and older adults? J. Physiol., June 1, 2008; 586(11): 2673 - 2674. [Full Text] [PDF] |
||||
![]() |
P. M. Vanhoutte Arginine and Arginase: Endothelial NO Synthase Double Crossed? Circ. Res., April 25, 2008; 102(8): 866 - 868. [Full Text] [PDF] |
||||
![]() |
S. Ryoo, G. Gupta, A. Benjo, H. K. Lim, A. Camara, G. Sikka, H. K. Lim, J. Sohi, L. Santhanam, K. Soucy, et al. Endothelial Arginase II: A Novel Target for the Treatment of Atherosclerosis Circ. Res., April 25, 2008; 102(8): 923 - 932. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. S. Katusic Mechanisms of Endothelial Dysfunction Induced by Aging: Role of Arginase I Circ. Res., September 28, 2007; 101(7): 640 - 641. [Full Text] [PDF] |
||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2007 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |